Center for Personalized Cancer Medicine GmbH

Innsbruck, Austria

Center for Personalized Cancer Medicine GmbH

Innsbruck, Austria

Time filter

Source Type

Schnaiter S.,Center for Personalized Cancer Medicine | Furst B.,Innsbruck Medical University | Neu J.,Center for Personalized Cancer Medicine | Waczek F.,Vichem Chemie Ltd. | And 4 more authors.
Methods in Molecular Biology | Year: 2014

Several essential cellular functions are critically influenced by the Ras-Raf-MEK-ERK cascade, and pathological problems have been implicated with loss as well as gain of its activity. Therefore, there is a great demand for chemical probes that act as modulators of the cascade in order to correct medical problems associated with its malfunctions. Here we describe the use of the In-Cell Western assay, a fast and easy method for the detection of ERK activity. This method is useful for the screening of chemical libraries for compounds that modulate the intensity and duration of growth factor-induced MAPK activity. Examples are provided from a screen for MAPK modulators in Vichem Chemie Research́s Nested Chemical Library™. © 2014 Springer Science+Business Media, LLC.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: INNOSUP-1-2015 | Award Amount: 4.98M | Year: 2016

It is the aim of PERMIDES to strenghten the competitiveness and foster the innovation potential of Personalized Medicine as an Emerging Industry in Europe by providing key solutions for the reconfiguration of the biopharmaceutical value chain towards a Health Economy 4.0 with a special focus on oncology (i.e. cancer treatment). Current value chain challenges lie in e.g. data gathering and exchange, big data and machine learning, or new software-based marketing methods based. Via a cross-clustering approach, leading biopharma and IT clusters from three countries (Austria, Germany and Norway) will create novel cross-sectoral collaborations between SMEs to address innovation barriers in the biopharma sector via cutting-edge IT solutions. As a cross-cutting industry, the ICT and software sector is an enabler of innovation in many industries and therefore provides a broad knowledge base of processes and best practice solutions in diverse industrial contexts and business environments. PERMIDES will create an collaboration space consisting of workshops, a semantic online matchmaking portal complemented by matchmaking events that will allow biopharma enterprises to identify the most suitable ICT company from the participating clusters. In a second step, the biopharmaceutical SME and the ICT partner will jointly tackle an innovation barrier in the value chain using an innovation voucher scheme. Follow-up coaching and transfer activites by the cluster organisations will maximise the effect of around 90 collaborative projects that PERMIDES aims to achieve.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-05-2014 | Award Amount: 7.99M | Year: 2015

While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer. Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individuals risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells currently collected within cervical cancer screening provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Mllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of P4 Medicine (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tools output into personalised recommendations for screening and prevention of female cancers. Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.4.1-2 | Award Amount: 4.28M | Year: 2012

Multiple Myeloma (MM) is an incurable disease with rapidly growing prevalence and poor prognosis. Consequently, it is the goal of the OPTATIO consortium to seek out novel strategies for the development of novel diagnostic and therapeutic options. The MM pathogenesis involves not only genetic changes within the tumour cells but also the emergence of supportive conditions by the bone marrow microenvironment (BMM). To target the essential components of this support system, it is the goal of the project to establish preclinical in vitro and in vivo models of MM that include functionally relevant elements of the BMM. The OPTATIO consortium will therefore analyse clinical data to correlate the presence of particular MM-BMM interactions with the pathogenesis of MM, with its intrinsic therapy resistance as well as with disease relapse due to the development of acquired drug resistance. These correlative data will be validated using autologous MM-BMM co-culture assays and reverse translated into in vitro screening and in vivo models, which will be subsequently used to develop lead compounds that target myeloma cells within their microenvironment. The clinical expertise of several oncological divisions, the research experience of academic laboratories and the pharmaceutical know-how of small and medium sized enterprises as well as biotech industry joined their efforts within the OPTATIO consortium to drive this important development and to ensure translation towards clinical trials. Expected impacts of the project include establishment of better diagnostics, new drug screening approaches for MM and novel personalised therapies based on individual ex vivo phenotyping leading to reduced patient mortality. Since envisaged drug screening methods are applicable to other areas of research and development, the project results will open new markets for industry partners in the fields of drug discovery and pharmaceutical development of products and services for personalized medicine.


Huber L.A.,Center for Personalized Cancer Medicine GmbH | Huber L.A.,Innsbruck Medical University
Current Opinion in Molecular Therapeutics | Year: 2010

Pharmacogenetics, genomics and epigenetics have attracted the interest of both pharmaceutical research groups and the medical community. The promise of these rapidly developing research fields and the expected consequences for medicine and for the pharmaceutical industry are timely topics of interest in molecular therapeutics. Of particular interest is their role in supporting the ability to customize medical care to individual patients. © Thomson Reuters (Scientific) Ltd.


Snajder R.,Innsbruck Medical University | Snajder R.,Oncotyrol Center for Personalized Cancer Medicine GmbH | Trajanoski Z.,Innsbruck Medical University | Hackl H.,Innsbruck Medical University
Bioinformatics | Year: 2013

Summary: GPViz is a versatile Java-based software for dynamic gene-centered visualization of genomic regions and/or variants. User-defined data can be loaded in common formats as resulting from analysis workflows used in sequencing applications and studied in the context of the gene, the corresponding transcript isoforms, proteins and their domains or other protein features. Both the genomic regions and variants can be also defined interactively. Various gene filter options are provided to enable an intersection of variants, genomic regions and affected protein features. Finally, by using GPViz, we identified differentially expressed exons, which could indicate alternative splicing events, and found somatic variants in different cancer types affecting metabolic proteins. GPViz is freely available at http://icbi.at/gpviz (released under GNU general public license), is based on Java 7 and can be used as a stand-alone or Web Start application. Availability: http://icbi.at/gpvizContact: Supplementary information: Supplementary data are available at Bioinformatics online. © 2013 The Author.


Patent
Oncotyrol Center for Personalized Cancer Medicine GmbH | Date: 2014-09-03

The invention discloses a method for in vitro diagnosing a pancreas or colon cancer tissue specimen wherein the specimen is analysed for the presence or absence of the ectodomain of EpCAM (EpEX) as well as for the presence or absence of the intracellular domain of EpCAM (EpICD).


Patent
Oncotyrol Center for Personalized Cancer Medicine GmbH | Date: 2013-01-23

A method to determine the survival outcome of a breast cancer patient or to determine prognosis of a breast cancer patient, wherein the method comprises assaying a sample of breast cancer cells of the breast cancer patient for the expression level of CHAC1 transcript variants 1 and/or 2.


Patent
Oncotyrol Center for Personalized Cancer Medicine GmbH | Date: 2013-01-02

The invention discloses a method for detecting epithelial cell adhesion molecule (EpCAM) and/or the intracellular component of EpCAM (EpIC) and/or the extracellular region of EpCAM (EpEx) in a sample comprising the provision of a solid phase immunoassay wherein- either a monoclonal antibody recognising EpEx or a monoclonal antibody recognising EpIC is immobilised as a first antibody on a solid surface;- the first antibody is contacted with the sample to allow binding of EpCAM and/or EpIC and/or EpEx to the first antibody; and- the EpCAM and/or EpIC and/or EpEx bound to the first antibody is contacted with a second antibody being either a monoclonal antibody recognising EpIC or a monoclonal antibody recognising EpEx to allow binding of EpCAM and/or EpIC and/or EpEx bound to the first antibody to the second antibody; and- determining whether EpCAM and/or EpIC and/or EpEx have been recognised in the sample by the monoclonal antibodies.


Patent
Oncotyrol Center for Personalized Cancer Medicine GmbH | Date: 2012-12-26

The invention discloses a method for the preparation of stimulated cytotoxic ( and ) T cells and NK cells, comprising the following steps:- providing a preparation containing CD1b-positive (CD1b+) antigen presenting cells and responder lymphocytes (T cells and NK cells),- stimulating the preparation of CD1b+ antigen presenting cells and responder lymphocytes with an anti-CD1b antibody and interleukin 2 (IL-2), and- cultivating the stimulated CD1b+ antigen presenting cells and responder lymphocytes in a culture medium to obtain stimulated cytotoxic ( and ) T cells and NK cells.

Loading Center for Personalized Cancer Medicine GmbH collaborators
Loading Center for Personalized Cancer Medicine GmbH collaborators